


# XI SIMPOSIO INTERNACIONAL CÁNCER DE MAMA DE SANTIAGO 2018

CENTRO PARQUE - 18 AL 20 DE ABRIL - SANTIAGO - CHILE



## PROGRAM

Organizes:



Sponsor



Produces:



# XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

## INVITED PROFESSORS

**ADELA CAMUS, MD**, Gynecologist, Human Reproductive Center, Department of Gynecology, Clínica Las Condes, Santiago, Chile.

**ALEIX PRAT, MD**, Medical Oncologist, Head Medical Oncology Department, Associate Professor Hospital Clínic, University of Barcelona, Barcelona, Spain.

**ALLEN GABRIEL, MD**, Plastic Surgeon, Legacy Salmon Creek Medical Center and Peace Health Southwest Medical Center, Vancouver, USA.

**ALVARO IBARRA, MD**, Pathologist, Head Pathology Service, Clínica Las Condes, Santiago, Chile

**ANDRÉS MASCARÓ, MD**, Plastic Surgeon, Department of Plastic Surgery, Clínica Las Condes, Chile.

**ANTONIO SOLÁ, MD**, Radiation Oncologist, Cancer Center, Clínica Las Condes, Santiago, Chile.

**ARIEL FARIÑA, MD**, Radiation Oncologist, Arturo López Pérez Foundation, Chile.

**AUGUSTO LEÓN, MD**, Professor of Surgery, Surgical Oncologist, Head Program of Cancer Catholic University, School of Medicine, Santiago, Chile.

**CARLOS ARTEAGA, MD**, Medical Oncologist, Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center. Associate Dean of Oncology Programs, Dallas, USA.

**CÉSAR SÁNCHEZ, MD**, Medical Oncologist, Catholic University School of Medicine, Santiago, Chile.

**CHRISTINA ADANIEL, MD**, Medical Oncologist, Sótero del Río Hospital and Cancer Center, Clínica Las Condes, Santiago, Chile.

**ELISA PEREIRA, MD**, Immunologist, Medical Director, MSD Chile, Santiago, Chile.

**EVA CIRUELOS, MD**, Medical Oncologist. Breast Cancer Unit, Hospital 12 de Octubre, Associate professor, Complutense University, Madrid, Spain.

**FELIPE CARVAJAL, MD**, Radiation Oncologist, National Cancer Institute, Chile.

**HERNANDO PAREDES, MD**, Breast Surgeon, Head of Breast Center, Clínica Las Condes, Santiago, Chile.

**JAUME MASIÁ, MD**, Plastic Surgeon, Head, Plastic and Reconstructive Surgery Department. Hospital de la Santa Creu i Sant Pau and Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.

**JAVIER RETAMALES, MD**, Radiation Oncologist, University of Chile.

**JENIFFER BELLON, MD**, Radiation Oncologist, Director, Breast Radiation Oncology Institute Physician. Associate Professor of Radiation Oncology, Harvard Medical School Dana Farber Cancer Institute and Harvard Medical School, Boston, USA.

**JUAN M. DONAIRE, MD**, Breast Surgeon, Breast Center, Clínica Las Condes, Santiago, Chile.

**KEVIN HUGHES, MD, FACS**, Co-Director, Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Associate Professor of Surgery Harvard Medical School, Medical Director Bermuda Cancer Genetics and Risk Assessment Clinic, Boston, USA.

**LAURA GARCÍA ESTÉVEZ, MD**, Leader of Breast Cancer Program. MD Anderson Cancer Center, Head, Breast Unit, Comprehensive Oncology Center Clara Campal, (CIOCC), HM Hospitals, Madrid, Spain.

**LAURA ITRIAGO, MD**, Medical Oncologist, Director for Cancer Prevention, Cancer Center, Clínica Las Condes, Chile.

**MA. CRISTINA GASTÓ, MD**, Palliative Care Unit, Cancer Center, Clínica Las Condes, Chile.

**MARIANA CHÁVEZ-MACGREGOR, MD**, Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.

**MOTHAFAR RIMAWI, MD**, Medical Oncologist, Medical Director Smith Breast Center, Baylor College of Medicine, Houston, USA.

**NUVIA ALIAGA, MD**, Breast Surgeon, Breast Center, Clínica Las Condes, Santiago, Chile.

**PASCAL BALTZER, MD**, Radiologist. Department of Biomedical Imaging and Image-Guided Therapy, Medical University and General Hospital of Vienna, Austria.

**RICARDO ARMISEN, MD**, Center for Excellence in Precision Medicine Pfizer, Santiago, Chile.

**ROBERTO TORRES, MD**, Medical Oncologist, National Cancer Institute Hospital, Santiago, Chile.

**SERGIO QUEZADA, PhD**, Group Leader, Immune Regulation and Tumor Immunotherapy Lab, University College of London Cancer Institute, England. (TBC)

**SOLEDAD TORRES, MD**, Breast Surgeon, Breast Center, Clínica Las Condes, Santiago, Chile.

**SUSANA BENÍTEZ, MD**, Plastic Surgeon, Department of Plastic Surgery, Clínica Las Condes, Santiago, Chile.

**VERÓNICA ROBERT, PHD**, Psychologist, Head of Psychology Cancer Patients Support Program, Clínica Las Condes, Santiago, Chile.

# XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

## Wednesday April 18th, 2018

Salón del Parque III

08:00 - 12:00 **NEW ADVANCES IN RECONSTRUCTIVE SURGERY.**

08:30 - 08:40 Welcome and introduction. **Md. Hernando Paredes**

### **BREAST RECONSTRUCTION AND RADIOTHERAPY. ALTERNATIVES FOR BREAST RECONSTRUCTION IN IRRADIATED TISSUE.**

**Chairman:** **Md. Andrés Mascaró**

- 08:40 - 09:10 **Plenary Session:** Immediate breast reconstruction in previously irradiated breast. **Md. Allen Gabriel**
- 09:10 - 09:25 Radiotherapy over implant. **Md. Nuvia Aliaga**
- 09:25 - 09:40 Radiotherapy over tissue expander. **Md. Hernando Paredes**
- 09:40 - 10:10 Delayed Breast Reconstruction after radiotherapy: planning the alternatives.
- 09:40 - 09:55 Using flaps. **Md. Susana Benítez**
- 09:55 - 10:10 Using implants. **Md. Juan M. Donaire**
- 10:10 - 10:40 COFFEE BREAK

### **BREAST RECONSTRUCTION USING ADMs**

**Chairwoman:** **Md. Susana Benítez**

- 10:40 - 11:00 The evolution of breast reconstruction, from sub-pectoral to pre-pectoral implant. **Md. Jaume Masiá**
- 11:00 - 11:20 Early outcomes in submuscular versus prepectoral ADM assisted breast reconstruction. **Md. Allen Gabriel**
- 11:20 - 11:40 Early outcomes in cost-effectiveness and functionality in pre-pectoral ADM covered implant versus sub-muscular breast reconstruction. **Md. Jaume Masiá**
- 11:40 - 12:00 Pre-pectoral breast reconstruction. How to avoid complications?. **Md. Allen Gabriel**
- 12:00 - 12:10 **Questions and Answers.**
- 12:15 - 13:30 Salón del Parque I - **Industry Symposium:** "Immune basis of solid tumors treatment" (Lunch included, limited capacity). **PhD. Sergio Quezada**

### **THE PENDING CHALLENGES OF DCIS**

**Chairs:** **Md. Jamile Camacho and Md. Eugenio Vinés**

- 13:40 - 14:00 Is over-diagnosis a problem?. **Md. Augusto León**
- 14:00 - 14:20 Active surveillance/de-escalation of therapy approach for low risk DCIS and the importance of margins. **Md. Kevin S. Hughes**
- 14:20 - 14:40 Radiotherapy for DCIS. **Md. Antonio Solá**

### **HOW TO SUPPORT OUR SURVIVING PATIENTS**

**Chairwomen:** **Ms. Advocacy Margarita Prieto and Ms. Advocacy Angélica Peñailillo**

- 14:40 - 15:00 The emotional and sexual problems of breast cancer survivors. **Phs. Verónica Robert**
- 15:00 - 15:20 How to manage late side effects in surviving patients, including life style. **Md. Laura Itriago**
- 15:20 - 15:40 Prevention of chemotherapy induced alopecia and potential role of cooling caps. **Md. Christina Adaniel**
- 15:40 - 16:00 COFFEE BREAK

# XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

## RADIOTHERAPY CONTROVERSIES

**Chairman:** Md. Pelayo Besa

- 16:00 - 16:20 Accelerated Partial breast irradiation: Intra, pre-or post-surgery. Md. Ariel Fariña  
16:20 - 16:40 Radiotherapy and breast reconstruction. Md. Javier Retamales  
16:40 - 17:00 State of the Art in hypo-fractionated radiotherapy schedules. Md. Felipe Carvajal

## ADVANCES IN BREAST RADIOLOGY

**Chairwomen:** Md. Marcela Jacard and Md. Paulina Neira

- 17:00 - 17:20 Limitations of Breast MRI and how to address them. Md. Pascal Baltzer  
17:20 - 17:40 MRI as a biomarker for diagnostic and prognostic purposes. Md. Pascal Baltzer  
17:40 - 18:00 MRI for screening purposes: Ultrashort enhanced protocols or DWI only?. Md. Pascal Baltzer  
18:00 - 18:10 **Questions and Answers.**  
18:10 - 19:30 Clinical cases session focused on MRI.

## Thursday April 19, 2018

- 08:30 - 08:40 Opening remarks and Welcome.  
Md. Soledad Torres, Md. Hernando Paredes and Md. José Miguel Reyes

## WHAT HAVE WE LEARNED FROM NEO-ADJUVANT TREATMENT?

**Chairs:** Md. Christina Adaniel and Md. Eduardo Yañez

- 08:40 - 08:47 Evaluation of the results of neoadjuvant chemotherapy for breast cancer in a Health Service: pathological complete response and survival. Md. Militza Petric  
08:47 - 09:00 **Questions and Answers.**  
09:00 - 09:05 Discussion by Md. Mariana Chavez-Macgregor  
09:05 - 09:25 The benefits of neo-adjuvant therapy according to molecular subtypes.  
Md. Mariana Chavez-Macgregor  
09:25 - 09:45 Neo-adjuvant endocrine treatment: How to select the appropriate patient and how to evaluate response. Md. Mothafar Rimawi  
09:45 - 09:52 Contrast-enhanced mammography for breast cancer detection: two years' experience in Santiago, Chile. Md. Catalina Vial  
09:52 - 09:55 **Questions and Answers**  
09:55 - 10:00 Discussion by MD. Pascal Baltzer  
10:00 - 10:20 MRI in the assessment of neoadjuvant treatment response. Md. Pascal Baltzer  
10:20 - 10:45 COFFEE BREAK  
10:45 - 10:50 Opening Remarks. Md. May Chomali  
10:50 - 10:57 Access to breast cancer treatment differences in Chilean women according to health insurance system. Md. Tomás Merino  
10:57 - 11:00 **Questions and Answers**  
11:00 - 11:05 Discussion by Md. May Chomali  
11:05 - 11:12 Management of the axilla in early breast cancer patients treated with neoadjuvant chemotherapy in a private center in Chile. Md. Marcela Amar

# XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

11:12 - 11:15 **Questions and Answers.**

11:15 - 11:20 Discussion by **Md. Kevin S. Hughes**

11:20 - 11:40 Is surgery of the breast & the axilla mandatory in complete responders to neo-adjuvant treatment?. **Md. Kevin S. Hughes**

11:40 - 12:00 Radiotherapy after neo-adjuvant treatment. **Md. Jennifer Bellon**

12:00 - 13:00 Clinical cases discussion (loco - regional). **Md. Soledad Torres**

13:00 - 14:30 Industry Symposium: "Navigating Her 2 positive eBC treatment. What can we learn from clinical practice and trial data?". **Md. Eva Ciruelos**

## OVERCOMING ENDOCRINE RESISTANCE

**Chairs: Md. Laura Itriago and Md. Alejandro Acevedo**

14:30 - 14:50 Palbociclib, ribociclib or amebaciclib: Are all the same? Mechanisms of action and clinical results. **Md. Mariana Chavez-Macgregor**

14:50 - 15:10 CDK4/6 inhibitors, how do they work? Why only in ER+ tumors? Are they different? Mechanisms of resistance. **Md. Carlos Arteaga**

15:10 - 15:30 When and who benefits with everolimus or other PIK3CA inhibitors?. **Md. Eva Ciruelos**

15:30 - 15:37 Neutrophil/lymphocyte ratio as a neoadjuvant chemotherapy predictor. **Md. Mauricio Rivas**

15:37 - 15:40 **Questions and Answers.**

15:40 - 15:45 Discussion by **Md. Aleix Prat**

15:45 - 16:05 Prognostic and predictive biomarkers in HR+/HER2- negative advanced/ metastatic breast cancer. **Md. Aleix Prat**

10:05 - 16:30 COFFEE BREAK

## ESCALATING AND DE-ESCALATING TREATMENT INTENSITY

**Chairs: Md. Antonio Solá and Md. Ricardo Schwartz**

16:30 - 16:50 Role of the pathologist for breast cancer treatment: de-escalation and escalation of therapy. **Md. Alvaro Ibarra**

16:50 - 17:10 Molecular platforms. Utility and assay comparison. **Md. Laura García Estévez**

17:10 - 17:30 Endocrine therapy: 10 years or more for all ER/PgR positive patients? Or Less than 10 years for some of them?. **Md. Mothafar Rimawi**

17:30 - 17:37 Axillary dissection after positive sentinel lymph node. **Md. Yocelyn Palta**

17:37 - 17:40 **Questions and Answers.**

17:40 - 17:45 Discussion by **Md. Kevin S. Hughes**

17:45 - 18:05 Which patients benefit from axillary dissection?. **Md. Kevin S. Hughes**

18:05 - 18:25 Which patients do not benefit from radiotherapy?. **Md. Jennifer Bellon**

18:25 - 18:45 De-escalating systemic treatment in HER2+ disease. **Md. Aleix Prat**

18:45 Industry Symposium: "Redefining first line in metastatic breast cancer". **Md. Carlos Arteaga**



# XI SANTIAGO INTERNATIONAL BREAST CANCER SYMPOSIUM

**Friday, April 20th**

## **FACING PROBLEMS OF VERY YOUNG PATIENTS WITH BREAST CANCER**

**Chairs:** Md. Ma. Eugenia Bravo and Md. Manuel Yañez

- 08:30 - 08:50 Fertility preservation for women with or at risk of breast cancer: For mutation carriers, for women with breast cancer diagnoses. **Md. Adela Camus**
- 08:50 - 09:10 What to do with tamoxifen in women who desire pregnancy. **Md. César Sánchez**
- 09:10 - 09:30 Role of ovarian suppression in the adjuvant management of HR+/HER2- disease in very young patients. **Md. Roberto Torres**
- 09:30 - 09:50 Role of adjuvant chemotherapy for HR+/HER-2 negative disease in very young patients. **Md. Mothafar Rimawi**
- 09:50 - 10:10 Mechanisms of resistance to endocrine therapy: Bedside to bench approaches to identify them (PIK3CA, HER2 mutations, etc.). **Md. Carlos Arteaga**
- 10:10 - 10:40 COFFEE BREAK

## **METASTATIC AND RECURRENT DISEASE**

**Chairs:** Md. Jorge Gutiérrez and Md. Claudio Salas

- 10:40 - 11:00 When to introduce supportive care in advanced breast cancer. **Md. Cristina Gastó**
- 11:00 - 11:20 Personalized medicine in breast cancer: The role of next generation sequencing. **Md. Ricardo Armisen**
- 11:20 - 11:40 PARP inhibitors: Only useful for triple negative disease? Clinical data and future perspectives. **Md. Aleix Prat**
- 11:40 - 11:50 **Questions and Answers.**
- 11:50 - 12:50 Clinical cases Discussion (Advanced Disease).
- 13:00 - 14:30 Salón del Parque I - **Industry Symposium:** "Management of advanced breast cancer ER + Her2 -" **MD. Mariana Chavez-Macgregor**  
**Chairs:** Md. Luis Cereceda and Md. Claudia Gamargo
- 14:30 - 14:50 New data and new drugs for HER-2 positive disease. **Md. Eva Ciruelos**
- 14:50 - 15:10 Molecular classification of triple negative disease: which one is best?. **Md. Aleix Prat**
- 15:10 - 15:30 Immune therapy for triple negative breast cancer. **Md. Elisa Pereira**
- 15:30 - 15:50 Immune therapy: The future for breast cancer?. **Phd. Sergio Quezada**
- 15:50 - 16:15 COFFEE BREAK  
**Chairs:** Md. Constanza Rojas and Md. Militza Petric
- 16:15 - 16:35 Management of ipsilateral breast tumor recurrence after conservative surgery, is mastectomy mandatory?. **Md. Soledad Torres**
- 16:35 - 16:55 How to manage the systemic treatment after loco-regional recurrence?. **Md. Mothafar Rimawi**
- 16:55 - 17:15 Role of surgery in the management of oligo-metastatic breast cancer. Does the molecular sub-type matter?.
- 16:55 - 17:05 The surgeon perspective. **Md. Juan M. Donaire**
- 17:05 - 17:15 The medical oncologist point of view. **Md. Mariana Chavez-Macgregor**  
**Chairman:** Md. Octavio Peralta
- 17:15 - 17:45 **Plenary conference:** Genetic testing for hereditary breast cancer. **Md. Kevin S. Hughes**